Donanemab—one of the two breakthrough therapies hailed globally for showing promising results in treating Alzheimer’s disease—has been approved by India’s apex drug regulator, and its maker Eli Lilly and Company is preparing to launch it within a few months.

The drug, administered as monthly injections, is an amyloid-targeting treatment for people with mild cognitive impairment (MCI) as well as those in the mild dementia stage of early symptomatic Alzheimer’s disease, the most common form of dementia.

Monoclonal antibodies are laboratory-made proteins designed to bind to specific targets in the body and are used to treat various conditions, including cancer.

Donanemab, following lecanemab by Eisai and Biogen, is the second monoclonal antibody approved in many countries for treating Alzh

See Full Page